OPKO Health, Inc. OPK and ChromaDex Corporation CDXC
announced today they have entered into a strategic alliance pursuant to which
ChromaDex has licensed to OPKO all of its new product offerings and health
care technologies for distribution and business development throughout all of
Latin America. The initial products to be commercialized are BlūScience™
(www.bluscience.com), ChromaDex's recently launched line of dietary
supplements, as well as ChromaDex's proprietary pterostilbene, branded as
pTeroPure® (www.pteropure.com). OPKO recently made a $1,000,000 investment in
ChromaDex as a participant in a private placement of 4,993,329 shares of
ChromaDex common stock.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in